A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
SparkCures ID | 1301 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 24 Patients |
Treatments |
|
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersRead the latest news and updates on this trial.
Learn more about how we work with trial sponsors